ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Sees Large Growth in Short Interest

Posted by Sam Norman on Jan 29th, 2025

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 41,800 shares, an increase of 305.8% from the December 31st total of 10,300 shares. Based on an average daily trading volume, of 12,800 shares, the short-interest ratio is currently 3.3 days.

Institutional Investors Weigh In On ProShares UltraShort Nasdaq Biotechnology

A hedge fund recently bought a new stake in ProShares UltraShort Nasdaq Biotechnology stock. Jane Street Group LLC acquired a new stake in shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 10,520 shares of the company’s stock, valued at approximately $158,000. Jane Street Group LLC owned about 4.78% of ProShares UltraShort Nasdaq Biotechnology as of its most recent SEC filing.

ProShares UltraShort Nasdaq Biotechnology Price Performance

Shares of BIS stock opened at $16.56 on Wednesday. ProShares UltraShort Nasdaq Biotechnology has a one year low of $14.05 and a one year high of $21.10. The company’s 50-day moving average is $17.28 and its 200 day moving average is $15.89.

ProShares UltraShort Nasdaq Biotechnology Increases Dividend

The company also recently declared a dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 23rd were issued a dividend of $0.2064 per share. This is a boost from ProShares UltraShort Nasdaq Biotechnology’s previous dividend of $0.15. The ex-dividend date of this dividend was Monday, December 23rd.

About ProShares UltraShort Nasdaq Biotechnology

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.